Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2020-04-08 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
2019年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2019 Annual General Meeting Resolution Announcement" for 普洛药业股份有限公司. It details the resolutions passed at the 2019 Annual General Meeting (AGM), including voting results on various proposals such as the annual report, board reports, financial statements, profit distribution, election of directors and supervisors, and amendments to company bylaws. The document includes attendance details, voting methods, and legal opinions confirming the validity of the meeting and resolutions. There is no indication that this document is the full annual report or financial statements themselves, but rather it is an official announcement of the voting results and resolutions passed at the AGM. The document length is 7055 characters, which is consistent with a detailed announcement rather than a full report. Therefore, this document fits the category of "Declaration of Voting Results & Voting Rights Announcements" (DVA).
2020-04-08 Chinese
关于召开2019年年度股东大会的提示性公告
AGM Information Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2019 Annual General Meeting (AGM) of 普洛药业股份有限公司. It includes information about the meeting date, voting procedures, proposals to be discussed and voted on, including the 2019 annual report, board and supervisory reports, financial statements, profit distribution plan, election of directors and supervisors, and amendments to company bylaws. The document also contains instructions for shareholders on how to participate in the meeting and vote, including proxy forms and voting codes. The content is focused on informing shareholders about the AGM logistics and agenda rather than presenting the actual annual report or financial statements themselves. The document length is 6347 characters, which is relatively short and consistent with an announcement or notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or notices related to it.
2020-03-30 Chinese
关于公司购买的理财产品到期赎回的公告
Capital/Financing Update Classification · 95% confidence The document is a company announcement regarding the maturity and redemption of financial products purchased by the company using idle funds. It details amounts, dates, and returns on these financial products. The document is short (1190 characters) and serves as a disclosure or update about financial product transactions, not a full financial report or audit. It does not contain financial statements or detailed financial analysis. It is an announcement about capital management activities related to financing and investment products. Therefore, it fits best under Capital/Financing Update (CAP).
2020-03-25 Chinese
独立董事关于对公司购买基金资管产品暨关联交易事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from the independent directors of 普洛药业股份有限公司 regarding a related-party transaction involving the company's purchase of fund management products. It references compliance with regulatory guidelines and company rules, and it is a formal statement of opinion rather than a financial report or announcement of voting results. The document length is short (593 characters), and it does not contain financial statements or detailed financial data. It is not an announcement of a report publication or a certification letter. The content fits best under Regulatory Filings (RNS) as it is a formal regulatory disclosure related to corporate governance and compliance with laws regarding related-party transactions.
2020-03-24 Chinese
第七届监事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a resolution passed at the 17th meeting of the 7th Supervisory Board of 普洛药业股份有限公司. It includes details about the meeting date, attendance, and the voting result on a specific agenda item regarding the use of idle funds to purchase fund management products, which is an internal corporate governance matter. The document does not contain financial statements, audit opinions, or detailed financial data. It is not a full report but an announcement of a board/management decision. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Confidence is high due to clear meeting and resolution content.
2020-03-24 Chinese
关于使用自有闲置资金购买基金资管产品暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 普洛药业股份有限公司 regarding the use of its own idle funds to purchase fund asset management products from a related party. It details the investment overview, related party information, independent directors' opinions, risk analysis, and impact on the company. The document is a formal disclosure of a financing-related transaction involving capital allocation and related-party dealings. It does not contain financial statements or quarterly/yearly financial results, nor is it a report or transcript. It is an update on a capital/financing activity, specifically the purchase of fund products using company funds. The document length is 3838 characters, which is relatively short but contains substantive information about the financing transaction itself, not just an announcement of a report. Therefore, it fits best under Capital/Financing Update (CAP).
2020-03-24 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.